Enzo Biochem Inc (ENZ) FinancialsENZEnzo Biochem Inc

Enzo Biochem Inc (ENZ) generates its revenue primarily from Products, which accounts for 100.0% of total sales, equivalent to $7.33M. Understanding this concentration is critical for investors evaluating how ENZ navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Enzo Biochem Inc maintains a gross margin of 51.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -17.07%, while the net margin is -17.02%. These profitability ratios, combined with a Return on Equity (ROE) of -12.94%, provide a clear picture of how effectively ENZ converts its operational activities into shareholder value.

In the context of the broader market, ENZ competes directly with industry leaders such as IXHL and UBX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ENZ's gross margin of 51.61% stands against IXHL's N/A and UBX's N/A. Such benchmarking helps identify whether Enzo Biochem Inc is trading at a premium or discount relative to its financial performance.